Australia · Delayed Price · Currency is AUD AdAlta Earnings Call Transcripts
Fiscal Year 2026
-
BZDS1901, a CAR T-cell therapy for mesothelioma, has shown unprecedented complete response rates in advanced patients and is positioned for global expansion via an East to West strategy. Manufacturing and clinical milestones are progressing, with a phase I Australian trial targeted for late 2027.
-
A new CAR-T cell therapy for mesothelioma, BZDS1901, has been in-licensed and will undergo Phase I trials in Australia, targeting a $4.2 billion market. Early clinical data show strong efficacy, and the program is structured for capital efficiency and rapid value creation.
Fiscal Year 2025
-
A new East-to-West cell therapy strategy is driving growth, with three solid tumor assets under negotiation and a capital-light, scalable business model. AD-214 and WD-34 remain available for partnering, while financing efforts focus on advancing clinical-stage assets.
-
Two-pronged strategy focuses on scaling cell therapy for solid cancers via Asian partnerships and advancing AD-214 for fibrotic diseases through licensing or co-investment. Pipeline progress and leadership expansion position for transaction-driven growth in 2025.